Form 4: Ideaya Biosciences Director Terry J. Rosen Reports Stock Option Grant

Director Terry J. Rosen of Ideaya Biosciences reports the acquisition of stock options.

Summary

• On May 31, 2024, Terry J. Rosen, a director of Ideaya Biosciences, Inc., reported the acquisition of stock options.
• Rosen acquired options to purchase 16,200 shares of common stock at an exercise price of $36.55.
• The options vest on the earlier of the first anniversary of the grant date or immediately prior to the next Annual Meeting, contingent upon continued service on the Board.
• Rosen also has granted power of attorney to certain officers of Ideaya Biosciences, Inc. to execute and file forms on his behalf.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction (stock option grant) and power of attorney, suggesting a neutral to slightly positive sentiment due to alignment of director interests with shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of compensation for directors and executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants to board members are a common practice in the biotech industry.
• Comparable companies such as Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their compensation packages for directors.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term commitment and value creation.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates